@ADurbinLab
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
Clinician-scientist Pediatric Oncologist focusing on chemical epigenetics & transcriptional circuitries. Better treatments, less toxicity. @stjuderesearch
Memphis, TN
Joined April 2020
- Tweets1.1K
- Following993
- Followers1.3K
- Likes2.4K
So excited to work with @JunQiLab on this important study!
New research published in @JExpMed from @DanaFarber’s @JunQiLab and collaborators reveals that AKT inhibitors synergize with EP300 degraders to suppress osteosarcoma growth in vitro and in vivo. These agents positively combine across cancer cells in a manner dependent on control of protein synthesis.
➡️bit.ly/4z13y9G
Adam Durbin retweeted
Researchers identified a potential therapeutic vulnerability in a subset of osteosarcoma. In preclinical models, combining EP300 degradation with AKT inhibition slowed tumor growth and prolonged survival. The findings suggest a potential path toward more personalized treatment. bit.ly/3U3DwDt
Online today in @JExpMed,
doi.org/10.1084/jem.20251898
TLDR: a genetically-defined group of osteosarcoma is sensitive to the EP300 PROTAC JQAD1, due to a balance between degradation and resynthesis by the ribosome. Read on for deets...
This work sets the stage for future work testing more drug-like EP300 degraders with AKT inhibitors in osteosarcoma and indeed, across many, many other types of cancer.
We are grateful to the funders of this work for their support: @theNCI @NIH @StJudeResearch @StJude @hopeonwheels @CureSearch @RallyFoundation @ALSFNews @TheVFoundation @curingcancer and the Pediatric Dependencies Accelerator.
Looking for a post-doctoral fellowship in computational biology, focused on answering important questions in childhood cancer? Why wait? Apply now!
This position bridges the brilliant Brian J. Abraham lab computation with experimentation in the Adam Durbin lab @StJudeResearch.
Competitive candidates have a computational background, as described in the application post below.
Come join us and make a difference!
talent.stjude.org/careers/Jo…
@TheAbraLab @StJudeResearch @MolOnc_StJude
How “specific” are the inhibitors we use? In @nchembio, Sterling and Holtsmark et al reveal a dual inhibitory role for the clinical agent zavondemstat! Findings with implications for target and patient selection in trials, discussed by Drs Ali Nezhady and McKay-Corkum.
And our commentary here:
rdcu.be/M1KFeo4zzJfa
This perhaps explains some of the exceptional activity in #neuroblastoma. @theNCI @RallyFoundation @ALSFNews @DamonRunyon @thesgconline